Dror Chevion
Co-founder & CEO
Claimed by owner Concenter BioPharma
Former names:
Drugs for the Treatment and Prevention of Type 2 Diabetes
Concenter BioPharma
About
Concenter BioPharma develops drugs for treating and preventing type 2 diabetes. The company has developed a family of nonsteroidal chemical complexes made from components approved for clinical use. These new chemical entities constitute a protected platform of drugs with proven efficacy and safety.
The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.
Concenter BioPharma is a subsidiary of Silkim Pharma.
The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.
Concenter BioPharma is a subsidiary of Silkim Pharma.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
United States, Asia, Europe
The Team
(2)
PM(C
Prof. Mordechai (Mottie) Chevion
Co-founder & CSO
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
A Round
$2M
May 2016
$2M
Equity crowdfunding
$1.18M
Sep 2020
1 Investors
$1.18M
Media gallery
(2)
WCIRDC 2019 Winner w Bloomgarten
WCIRDC 2019 Winner
Locations
Israel
Israel
Locations
Israel
Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,